Agile Therapeutics (AGRX) PT Raised to $8 at RBC Capital After Twirla Approval
Tweet Send to a Friend
RBC Capital analyst Randall Stanicky raised the price target on Agile Therapeutics (NASDAQ: AGRX) to $8.00 (from $5.00) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
